Rapid Escalation of LipiD Lowering Therapy to Reduce RecUrrent Cardiovascular Event
REDUCE-Lipid
1 other identifier
observational
1,000
1 country
1
Brief Summary
Hyperlipidaemia especially elevation of low-density lipoprotein cholesterol (LDL-C) is known to be the main contributor to the development of atherosclerotic cardiovascular disease (ASCVD). Lowering LDL-C have been shown to reduce the risk of ASCVD2,3. Both the American Heart Association (AHA) and the European Society of Cardiology (ESC) advocated aggressive LDL-C target with statin being the first-line lipid-lowering therapy (LLT). However, a significant portion of patients did not attain their LDL-C goal in our locality. Statin no adherence, low uptake of adjuvant non-statin LLT, and therapeutic inertia are few potential causes for not achieving the LDL-C target. ESC recommends repeating blood test in 6-8 weeks after addition or alternation of LLT, but this recommendation was not routinely followed in current local practice due to resources constrain. This registry therefore aims to investigate the strategy of frequent monitoring of LDL-C and titration of LLT in achieving LDL-C treatment target at a dedicated specialist clinic.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2024
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 30, 2024
CompletedFirst Submitted
Initial submission to the registry
December 17, 2025
CompletedFirst Posted
Study publicly available on registry
December 31, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 30, 2031
December 31, 2025
December 1, 2025
6 years
December 17, 2025
December 17, 2025
Conditions
Outcome Measures
Primary Outcomes (8)
Low-density lipoprotein cholesterol (LDL-C) level
Absolute change in low-density lipoprotein cholesterol (LDL-C) level at baseline
Baseline
Low-density lipoprotein cholesterol (LDL-C) level
Absolute change in low-density lipoprotein cholesterol (LDL-C) level at week 8
week 8
Low-density lipoprotein cholesterol (LDL-C) level
Absolute change in low-density lipoprotein cholesterol (LDL-C) level at week 26
Week 26
Low-density lipoprotein cholesterol (LDL-C) level
Absolute change in low-density lipoprotein cholesterol (LDL-C) level at week 52
Week 52
Low-density lipoprotein cholesterol (LDL-C) level
Percentage change in low-density lipoprotein cholesterol (LDL-C) level at Baseline
Baseline
Low-density lipoprotein cholesterol (LDL-C) level
Percentage change in low-density lipoprotein cholesterol (LDL-C) level at week 8
Week 8
Low-density lipoprotein cholesterol (LDL-C) level
Percentage change in low-density lipoprotein cholesterol (LDL-C) level at week 26
Week 26
Low-density lipoprotein cholesterol (LDL-C) level
Percentage change in low-density lipoprotein cholesterol (LDL-C) level at week 52
Week 52
Secondary Outcomes (16)
Rate of subject meeting LDL-C target
Week 26
Rate of subject meeting LDL-C target
Week 26
Rate of subject meeting LDL-C target
Week 26
12-Item Short Form Survey (SF-12)
Baseline
12-Item Short Form Survey (SF-12)
Week 8
- +11 more secondary outcomes
Study Arms (2)
Acute Coronary Syndrome
Patient with acute coronary syndrome due to atherosclerotic coronary artery disease
Chronic coronary syndrome
Patient with chronic coronary syndrome due to atherosclerotic coronary artery disease
Eligibility Criteria
Patients aged greater than 18 and who are admitted for a diagnosis of acute coronary syndrome (ACS) due to atherosclerotic coronary artery disease based on invasive coronary angiography will be recruited into this registry.
You may qualify if:
- Age \>18
- (Cohort 1) Diagnosis of acute coronary syndrome due to atherosclerotic coronary artery disease
- (Cohort 2) Diagnosis of chronic coronary syndrome due to atherosclerotic coronary artery disease
You may not qualify if:
- Inability to provide valid consent by the patient or his legal guardian
- Diagnosis of ACS due to other causes than atherosclerotic coronary artery disease.
- Psychiatric or severe neurological disorder, cirrhosis, or active malignancy leading to a life expectancy \< 6 months.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Prince of Wales Hospital
Shatin, New Terrritories, 999077, Hong Kong
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinical Assistant Professor
Study Record Dates
First Submitted
December 17, 2025
First Posted
December 31, 2025
Study Start
December 30, 2024
Primary Completion (Estimated)
December 31, 2030
Study Completion (Estimated)
June 30, 2031
Last Updated
December 31, 2025
Record last verified: 2025-12
Data Sharing
- IPD Sharing
- Will not share